Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors
Completed
- Conditions
- Hepatitis C Virus
- Registration Number
- NCT00819026
- Lead Sponsor
- University of Wisconsin, Madison
- Brief Summary
Hepatitis C Virus is constantly evolving genetically, particularly in response to the immune system. This is an observational study to examine if immunosuppressants particularly calcineurin inhibitors taken by transplant patients in order to avoid organ rejection causes predictable changes in the genetics of this virus that might be important in order to treat it effectively.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- HCV infected on immunosuppression
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link calcineurin inhibitors to Hepatitis C virus genetic evolution in transplant patients?
How do calcineurin inhibitors compare to standard-of-care antiviral therapies in managing HCV in transplant recipients?
Which biomarkers correlate with HCV response to immunosuppressants like cyclosporine or tacrolimus in transplant patients?
What adverse events are associated with calcineurin inhibitor use in HCV-infected transplant recipients and how are they managed?
Are there combination therapies involving calcineurin inhibitors and direct-acting antivirals that improve HCV outcomes in transplant patients?
Trial Locations
- Locations (1)
University of Wisconsin
🇺🇸Madison, Wisconsin, United States
University of Wisconsin🇺🇸Madison, Wisconsin, United States